{"id":"NCT02134210","sponsor":"Coherus Biosciences, Inc.","briefTitle":"Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)","officialTitle":"A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06-16","primaryCompletion":"2015-07-27","completion":"2016-05-12","firstPosted":"2014-05-09","resultsPosted":"2019-05-13","lastUpdate":"2019-06-28"},"enrollment":521,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"Etanercept","otherNames":["Enbrel","European Enbrel"]},{"type":"DRUG","name":"CHS-0214","otherNames":[]}],"arms":[{"label":"Enbrel (etanercept)","type":"ACTIVE_COMPARATOR"},{"label":"CHS-0214","type":"EXPERIMENTAL"}],"summary":"This is a two part study comparing CHS-0214 to Enbrel in patients with chronic plaque PsO who have not yet received any biologic therapy for any indication (other than insulin or hormones).","primaryOutcome":{"measure":"Proportion of Subjects Achieving PASI-75(75% Improvement in Psoriasis Area and Severity Index) From Baseline at Week 12","timeFrame":"12-weeks","effectByArm":[{"arm":"Enbrel (Etanercept)","deltaMin":142,"sd":null},{"arm":"CHS-0214","deltaMin":147,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":100,"countries":["United States","Australia","Canada","Germany","Israel","Poland","South Africa"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":260},"commonTop":["Nasopharyngitis","Injection Site Reaction","Upper Respiratory Infection","Hypertension","Psoriasis"]}}